News | June 21, 2026
LabGenius and LG Chem strike AI-powered deal to develop next-gen tumour-targeting antibody therapy
The collaboration is focused on overcoming a major limitation in existing cancer drugs
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
LG Chem will receive totaling up to $95.5 million for the China rights
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
